Abiopharma

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Change in interest of Director - Ow Chio Kiat

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

VisionWave Unveils Combat-Ready TALON™ and D-FLY™ Autonomous Drone Platforms at Eurosatory 2026, Expanding STRATUM™ Battlefield Autonomy Ecosystem

Veea Inc. and TROLLEE Holdings Ltd. Extend Strategic Partnership to Deliver a Highly Advanced AI-Powered Autonomous Retail Ecosystem

RingCentral Expands AIR Pro to Deliver Agentic AI Capabilities Across Customer Engagement Portfolio

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Youlife Partners with Thingo Technology to Provide AI-powered Workforce Solutions Across China

Contango Silver & Gold Provides Project Updates

Idaho Copper Corp. Announces Anticipated Uplisting to the NYSE American Stock Exchange